SP
Therapeutic Areas
Neuphoria Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| BNC210 | Post-Traumatic Stress Disorder (PTSD) | Phase 3 (planning) |
| Next-Gen α7 NAM Program | CNS Disorders | Discovery/Preclinical |
| MK-1167 (via Merck) | Cognitive Dysfunction (Alzheimer's, Schizophrenia) | Phase 2 (imminent) |
| BNC101 (via Carina Biotech) | Solid Tumors | Out-licensed |